September 16, 2024

Development and validation of a prognostic signature of breast cancer based on drug absorption, distribution, metabolism and excretion (ADME)-related genes – Nature.com

September 15, 2024

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

New England Journal of Medicine, Ahead of Print.

September 15, 2024

NEJM at ESMO — Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer

New England Journal of Medicine, Ahead of Print.

September 15, 2024

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

New England Journal of Medicine, Ahead of Print.

September 15, 2024

NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

New England Journal of Medicine, Ahead of Print.